GPX4 and breast cancer: Studies have shown that FINs (such as RSL3, erastin, sorafenib, and sulfasalazine) can synergistically enhance RT efficacy by inhibiting SLC7A11 or inactivating GPX4 in models of glioma, lung cancer, fibrosarcoma, melanoma, breast cancer, and cervical cancer [60, 120, 126, 140–145].